Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Extension Study in CLL/SLL
NCT01724346Phase 3Completed
- Sponsor
- Pharmacyclics
- Start
- Dec 2013
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, open-label trial of ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Pharmacyclics. Primary endpoint: Progression Free Survival at 82.7 months. Started Dec 2013; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01724346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01724346.